http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-19990084528-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-252 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-252 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7028 |
| filingDate | 1998-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1999-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-19990084528-A |
| titleOfInvention | New anthracycline derivatives and preparation methods |
| abstract | The present invention relates to novel low cardiotoxic anthracycline derivatives and antitumor agents containing the same. Since anti-cancer antibiotics with quinone chemical structure continuously produce oxygen radicals such as superoxide in circulating redox reactions in vivo, the method of controlling the function of quinone reddactase becomes an efficient method of inhibiting oxygen radical generation. In view of the fact that it can be an important way to reduce the side effects of anthracycline-based anticancer antibiotics, the present inventors have found that radical generation, which is a factor of myocardial toxicity, can be regulated through correction of the NAD / NADH ratio. Therefore, the present invention invented an anthracycline derivative, a novel low cardiotoxic anticancer agent that controls the activity of oxygen radical synthase system by compensating the balance of intracellular NAD / NADH ratio. The novel anthracycline derivatives are prepared by ester-bonding with L-aspartate or pyruvate at position 14 of known anthracycline anticancer drugs, and their chemical structure and physical properties, stability tests, cardiotoxicity tests, and anticancer evaluation tests are performed. It was. As a result of the test, it was confirmed that the compound of the present invention is an excellent anticancer drug having excellent stability and anticancer activity similar to a known anthracycline-based anticancer substance, and having very reduced cardiotoxicity. This invention can be used as a drug for the treatment of cancer containing a novel anthracycline derivative with reduced cardiotoxicity. |
| priorityDate | 1998-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.